story of the week
Adjuvant Nivolumab Plus Ipilimumab or Nivolumab Alone vs Placebo in Patients With Resected Stage IV Melanoma With No Evidence of Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
Lancet 2022 Sep 09;[EPub Ahead of Print], E Livingstone, L Zimmer, JC Hassel, M Fluck, TK Eigentler, C Loquai, S Haferkamp, R Gutzmer, F Meier, P Mohr, A Hauschild, B Schilling, C Menzer, F Kiecker, E Dippel, A Roesch, M Ziemer, B Conrad, S Körner, C Windemuth-Kieselbach, L Schwarz, C Garbe, JC Becker, D SchadendorfFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.